Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID-19 vaccine with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter. According to the update, the groundbreaking vaccine technology being developed by Dr. Carter is based on … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates with Dr. Daniel Carter to Enter Race to Develop Potential COVID-19 Vaccine”
POAI CEO exchanges $2.1 promissory note for shares of common stock Agreement enables Predictive Oncology to strengthen balance sheet, simplify capital structure at critical juncture in quest to commercialize highly valuable database POAI cancels outstanding debt of $2,115,000 in aggregate principal amount of 12% promissory note Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Streamlines Capital, Simplifies Balance Sheet through Debt Exchange”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently reported that its Helomics subsidiary is making headway toward its goal of developing an AI-driven predictive model of ovarian cancer (http://nnw.fm/W2TJb). An article discussing the company reads, “This achievement will be a key milestone for … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing CancerQuest2020 Initiative”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Wednesday announced that it has entered into an exchange agreement with POAI chief executive officer Dr. Carl Schwartz regarding a $2.1 million promissory note of the company. Per the agreement, Dr. Schwartz has exchanged the … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Executes Agreement to Exchange $2.1M Debt for Equity”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its director and CEO Dr. Carl Schwartz was featured in an exclusive interview with NetworkNewsWire (“NNW”). In the interview, Dr. Schwartz discussed Predictive Oncology’s distinctive business model, as well as significant changes management … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Distinctive Business Model in Exclusive Interview”
Predictive Oncology (NASDAQ: POAI) operates through three segments (domestic, international and other) that contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. … Continue reading “NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) Interview”
Q4 highlights include $15 million equity line, CancerQuest 2020 initiative POAI revenues for FY 2019 total $1.4 million, primarily driven through sale of proprietary STREAMWAY units Predictive Oncology will continue to be pioneer in fields of biomarker discovery, precision therapies Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying its cutting-edge technology to cancer research, … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Releases FY Financials, Notes Key Partnerships, CancerQuest 2020 Milestones Achieved”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently entered into a securities purchase agreement with certain accredited investors to purchase shares of common stock (http://nnw.fm/r6SCU). An article discussing the company reads, “The company explained that it has entered into a securities purchase agreement with … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Securities Purchase Agreement to Raise $3.5 Million”
POAI’s Helomics division progresses toward critical milestone in CancerQuest2020 initiative Predictive models immensely valuable to pharmaceutical industry, improving drug evaluation without incurring high laboratory costs POAI is bringing precision medicine to the treatment of cancer for patients of today and tomorrow Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Continues Progress Toward AI-Driven Predictive Model of Ovarian Cancer”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced the launch of a new AI vaccine and drug development platform targeting coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS). An article discussing the company reads, “Through an interim operating agreement with Soluble … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Vaccine, Drug-Development Platform Targeting Coronaviruses, Acute Respiratory Syndromes”
